Trial Profile
Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors PharmaMar
- 01 Feb 2019 Results published in the Hematological Oncology
- 04 Dec 2018 Results evaluating safety and tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.